Ara 290 vs Semaglutide
Extensively Studied vs FDA Approved
compatible No adverse interactions in clinical trials with GLP-1 agonists.
Molecular Data
Ara 290 Semaglutide
Weight 1,257 Da 4,113.64 Da
Half-life ~20 minutes (SubQ), ~2 minutes (IV) ~7 days (168 hours)
Chain 11 amino acids 31 amino acids
Type Engineered peptide GLP-1 receptor agonist
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Ara 290 Semaglutide
Status Extensively Studied FDA Approved
References 5 studies 6 studies
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.